Difference between revisions of "Rest AP-Amisulpride"
From Psychiatrienet
| Line 1: | Line 1: | ||
{{Drugswitch | {{Drugswitch | ||
| − | | from = Rest AP | + | | from = Rest AP |
| + | | header = IntroRestAP | ||
| to = Amisulpride | | to = Amisulpride | ||
| stop = {{StopStand}} | | stop = {{StopStand}} | ||
Latest revision as of 11:04, 15 January 2013
| ||||||||||||||||||
| ||||||||||||||||||
Switch medication from Rest AP to Amisulpride.[1]
[2]
Rest AP is a collection of antipsychotic drugs having similar properties with respect to switching. A switch to member of the 'rest-AP' group from anotherdrug should be read as rest AP-anotherdrug. Similarly, a switch from a member of the 'rest-AP' group to anotherdrug should be read as anotherdrug-rest AP.
Stop Rest AP - Day 1-4: approx. 75% of initial dose
- Day 5-8: approx. 50% of initial dose
- Day 9-12: approx. 25% of initial dose
- Day 13: stop
Start Amisulpride- Day 1-4: approx. 25% of target dose
- Day 5-8: approx. 50% of target dose
- Day 9-12: approx. 75% of target dose
- Day 13: target dose
More information
— Rest AP — Amisulpride
- ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
